comparemela.com

Latest Breaking News On - L harbert institute for innovation - Page 1 : comparemela.com

Encouraging Phase 1 data for glioblastoma treatment

Preliminary clinical data for glioblastoma multiforme patients enrolled in a Phase 1 clinical trial demonstrated that 92 percent of evaluable patients treated with INB-200 exceeded a median progression-free survival of seven months with concomitant temozolomide chemotherapy. The median follow-up was 11.7 months. This survival data along with radiographic improvements are indicative of positive treatment effects, which highlights the potential of IN8bio s genetically modified, chemotherapy-resistant gamma-delta T cells as a potential first-in-class therapy for patients with newly diagnosed glioblastoma.

Students, graduates of UAB s award-winning public relations program command attention - News

Awards and honors continue for the PRCA/PRSSA at UAB chapter, where students put their classroom learning into real-world practice, preparing them for careers and vaulting them into the professional world. Students in UA.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.